search
Back to results

Vaginal Native Tissues Repair for Pelvic Organ Prolapse (TAPP)

Primary Purpose

Prolapse, Vaginal

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Anterior colporraphy
vaginal patch plastron
Sponsored by
University Hospital, Limoges
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Prolapse, Vaginal focused on measuring Prolapse, Vaginal native tissues repair, Pelvic organ

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient at 50 years of age or older
  • Symptomatic primary prolapse of the anterior vaginal wall defined by Aa and/or Ba points ≥0 according to the POP-Q system
  • A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20)
  • Able to give informed consent
  • Performans Status score ≤ 2

Exclusion Criteria:

  • Patient with need for surgical treatment for myorraphy of levator ani muscles
  • Patient with previous surgical cystocele repair.
  • Patient with evolving gynaecologic cancer.
  • Pregnancy or wish for future pregnancy, lactating woman.
  • Inability to participate in study follow-up or to provide informed consent.
  • Lack of social insurance .

Sites / Locations

  • CHU de BordeauxRecruiting
  • CH de BriveRecruiting
  • CHU de Clermont FerrandRecruiting
  • CH de GueretRecruiting
  • CHU de LimogesRecruiting
  • CHU de Saint-EtienneRecruiting
  • CHU de Toulouse - Paule de ViguierRecruiting
  • CHU de Toulouse - RangueilRecruiting
  • CH de TulleRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Arm A

Arm B

Arm Description

Outcomes

Primary Outcome Measures

Rate of the prolapse surgery
The success rate of the prolapse surgery defined by a composite of objective and subjective measures: Anatomic success defined by Aa and Ba values <0 in Pelvic Organ Prolapse Quantification System (POP-Q) AND Subjective success through reliable condition-specific quality-of-life questionnaires: A negative response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the Pelvic Floor Distress Inventory (PFDI-20)) AND Range score of Patient Global Impression of Improvement (PGI-I) 1 or 2 AND No need for other treatment for prolapse (surgical nor medical)

Secondary Outcome Measures

Rate of the prolapse surgery
The failure rate of the prolapse surgery defined by a composite of objective and subjective measures: Recurrent prolapse defined by Aa and/or Ba values > or= 0 in POP-Q OR Subjective failure through reliable condition-specific quality-of-life questionnaires: A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20) OR A PGI-I score > 2 OR Need of a new treatment for prolapse (surgical or medical)
Rate of post-operative complications
Rate of post-operative complications according to the Clavien-Dindo classification 45 days after the surgery by the patient's surgeon (not blinded)
Sexual function
The sexual function improvement will be evaluated by the difference in PISQ 12 score (condition-specific quality-of-life questionnaire) between the inclusion and one year after the surgery for sexually active women
Rate of the prolapse surgery
The failure rate of the prolapse surgery defined by a composite of objective and subjective measures: Recurrent prolapse defined by Aa and/or Ba values > or= 0 in POP-Q OR Subjective failure through reliable condition-specific quality-of-life questionnaires: A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20) OR A PGI-I score > 2 OR Need of a new treatment for prolapse (surgical or medical)
Rate of the prolapse surgery
The failure rate of the prolapse surgery defined by a composite of objective and subjective measures: Recurrent prolapse defined by Aa and/or Ba values > or= 0 in POP-Q OR Subjective failure through reliable condition-specific quality-of-life questionnaires: A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20) OR A PGI-I score > 2 OR Need of a new treatment for prolapse (surgical or medical)

Full Information

First Posted
March 13, 2019
Last Updated
August 28, 2023
Sponsor
University Hospital, Limoges
search

1. Study Identification

Unique Protocol Identification Number
NCT03875989
Brief Title
Vaginal Native Tissues Repair for Pelvic Organ Prolapse
Acronym
TAPP
Official Title
Vaginal Native Tissues Repair for Pelvic Organ Prolapse
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 27, 2019 (Actual)
Primary Completion Date
September 27, 2025 (Anticipated)
Study Completion Date
March 27, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Limoges

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the study is to assess at one year the effectiveness of the vaginal patch plastron in comparison of the anterior colporraphy through a combined definition of success: anatomic and functional.
Detailed Description
Pelvic organ prolapse is usually the result of loss of pelvic support. It is widely accepted that 50% of women after 50 years old will develop prolapse, evaluated through the POPQ Classification . Pelvic organ prolapse cause significant psychological distress and negatively affect quality of life. Among the surgery for prolapse, the cystocele cureis is the most frequent (67.7%). Native tissue cystocele repairs is the cornerstone of prolapse surgery especially since the learned societies (Food and Drug Administration, Haute Autorité de Santé, Collège National des Gynécologues-Obstétriciens Français) warned clinicians and patients about serious mesh related complications. In France, 41.5% of vaginal cystocele repair are with native tissue. The main surgeries are anterior colporraphy and vaginal patch plastron, used in routine in our center with re-intervention rates less than 4% at one year. Rate of success of native tissue cystocele repair are heterogeneous, depending on the design of studies and definition of outcomes. A prospective study find a success rate at 35% of the anterior colporraphy based on a combined definition, anatomic and functional as recommended recently. However the definition of anatomic was strict (POPQ<2), while it seems that the best definition of anatomic success is "no prolapse among the hymen", that is to say aAa and Ba points <0. We think that the vaginal patch plastron will have a better anatomic and functional success comparatively to the anterior colporraphy as it corrects median cystoceles by a vaginal strip as well as lateral cystoceles by the bilateral paravaginal suspension. The description of the two surgeries will be standardized between all the surgeons. We will compare the anterior colporraphy consisting in bladder median support by retensioning Halban fascia with colpectomy to the vaginal patch plastron consisting in making a vaginal strip attached to the bladder combined with suspension by fixation of the vaginal strip to the tendinous arch of the pelvic fascia. Patients will be blind of their surgery. They will have a follow-up visit 45 days after the surgery to evaluate the post- operative complications according to the Clavien-Dindo classification. They will have phone call at 4 and 8 months after the surgery to make sure they've not suffered for complications. At last, they will have a follow-up visit 1 year after the surgery by an independent assessor blind of the surgery to evaluate the primary outcome (anatomic and functional success).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prolapse, Vaginal
Keywords
Prolapse, Vaginal native tissues repair, Pelvic organ

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Experimental, parallel-group randomised controlled trial (1:1), multicentric. The primary outcome and the secondary outcome 1 and 3 will be evaluated in double blind; only the secondary outcome 2 will not be evaluated in blind.
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
214 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm A
Arm Type
Active Comparator
Arm Title
Arm B
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Anterior colporraphy
Intervention Description
It will be delimitate a rectangular vaginal strip which will be isolated from the anterior colpocele. The superior edge of the strip is placed 2 cm from the urethral orifice. After lateral vesico-vaginal dissection, the paravesical fossae will be wide opened to repair the tendinous arches. The vaginal plastron will be fixed to the tendinous arch of the pelvic fascia by 3 lateral stitches (anterior/ lateral/ posterior) on each side of the plastron. After, the plastron will be tensioning and the cystocele will be suspended. The closure of the vaginal wall will end the procedure.
Intervention Type
Procedure
Intervention Name(s)
vaginal patch plastron
Intervention Description
It will be make a midline incision of the anterior vaginal wall from the urethrovesical junction to the vaginal apex or anterior fornix. The vaginal epithelium will be separated from the underlying fibromuscular layer (Halban Fascia) after the midline incision. Midline plication of the fibromuscular layer will be obtained by interrupted horizontal stiches. The closure of the vaginal wall will end the procedure.
Primary Outcome Measure Information:
Title
Rate of the prolapse surgery
Description
The success rate of the prolapse surgery defined by a composite of objective and subjective measures: Anatomic success defined by Aa and Ba values <0 in Pelvic Organ Prolapse Quantification System (POP-Q) AND Subjective success through reliable condition-specific quality-of-life questionnaires: A negative response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the Pelvic Floor Distress Inventory (PFDI-20)) AND Range score of Patient Global Impression of Improvement (PGI-I) 1 or 2 AND No need for other treatment for prolapse (surgical nor medical)
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Rate of the prolapse surgery
Description
The failure rate of the prolapse surgery defined by a composite of objective and subjective measures: Recurrent prolapse defined by Aa and/or Ba values > or= 0 in POP-Q OR Subjective failure through reliable condition-specific quality-of-life questionnaires: A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20) OR A PGI-I score > 2 OR Need of a new treatment for prolapse (surgical or medical)
Time Frame
1 year
Title
Rate of post-operative complications
Description
Rate of post-operative complications according to the Clavien-Dindo classification 45 days after the surgery by the patient's surgeon (not blinded)
Time Frame
45 Days
Title
Sexual function
Description
The sexual function improvement will be evaluated by the difference in PISQ 12 score (condition-specific quality-of-life questionnaire) between the inclusion and one year after the surgery for sexually active women
Time Frame
1 year
Title
Rate of the prolapse surgery
Description
The failure rate of the prolapse surgery defined by a composite of objective and subjective measures: Recurrent prolapse defined by Aa and/or Ba values > or= 0 in POP-Q OR Subjective failure through reliable condition-specific quality-of-life questionnaires: A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20) OR A PGI-I score > 2 OR Need of a new treatment for prolapse (surgical or medical)
Time Frame
2 years
Title
Rate of the prolapse surgery
Description
The failure rate of the prolapse surgery defined by a composite of objective and subjective measures: Recurrent prolapse defined by Aa and/or Ba values > or= 0 in POP-Q OR Subjective failure through reliable condition-specific quality-of-life questionnaires: A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20) OR A PGI-I score > 2 OR Need of a new treatment for prolapse (surgical or medical)
Time Frame
3 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient at 50 years of age or older Symptomatic primary prolapse of the anterior vaginal wall defined by Aa and/or Ba points ≥0 according to the POP-Q system A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20) Able to give informed consent Performans Status score ≤ 2 Exclusion Criteria: Patient with need for surgical treatment for myorraphy of levator ani muscles Patient with previous surgical cystocele repair. Patient with evolving gynaecologic cancer. Pregnancy or wish for future pregnancy, lactating woman. Inability to participate in study follow-up or to provide informed consent. Lack of social insurance .
Facility Information:
Facility Name
CHU de Bordeaux
City
Bordeaux
ZIP/Postal Code
33000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claude HOCKE, MD
Email
claude.hocke@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Claude HOCKE, MD
First Name & Middle Initial & Last Name & Degree
Mathilde CORET, MD
First Name & Middle Initial & Last Name & Degree
Jean-Luc BRUN, MD
First Name & Middle Initial & Last Name & Degree
Géraldine CHAUVIN, MD
Facility Name
CH de Brive
City
Brive-la-Gaillarde
ZIP/Postal Code
19100
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christelle MESNARD, MD
Email
mesnardc@yahoo.fr
First Name & Middle Initial & Last Name & Degree
Christelle MESNARD, MD
First Name & Middle Initial & Last Name & Degree
Tristan GAUTHIER, MD
First Name & Middle Initial & Last Name & Degree
Dimitrios HARISIS, MD
Facility Name
CHU de Clermont Ferrand
City
Clermont-Ferrand
ZIP/Postal Code
63100
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sandrine CAMPAGNE, MD
Email
scampagne-loiseau@chu-clermontferrand.fr
First Name & Middle Initial & Last Name & Degree
Sandrine CAMPAGNE, MD
Facility Name
CH de Gueret
City
Guéret
ZIP/Postal Code
23000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yves AUBARD, MD
Email
yves.aubard@chu-limoges.fr
First Name & Middle Initial & Last Name & Degree
Yves AUBARD, MD
First Name & Middle Initial & Last Name & Degree
Aymeline LACORRE, MD
Facility Name
CHU de Limoges
City
Limoges
ZIP/Postal Code
87000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aymeline LACORRE, MD
Email
aymeline.lacorre@chu-limoges.fr
First Name & Middle Initial & Last Name & Degree
Tristan GAUTHIER, MD
Email
tristan.gauthier@chu-limoges.fr
First Name & Middle Initial & Last Name & Degree
Aymeline LACORRE, MD
First Name & Middle Initial & Last Name & Degree
Tristan GAUTHIER, MD
First Name & Middle Initial & Last Name & Degree
Yves AUBARD, MD
First Name & Middle Initial & Last Name & Degree
Hugues CALY, MD
First Name & Middle Initial & Last Name & Degree
Maxime LEGROS, MD
First Name & Middle Initial & Last Name & Degree
François MARGUERITTE, MD
Facility Name
CHU de Saint-Etienne
City
Saint-Étienne
ZIP/Postal Code
42000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Céline CHAULEUR, MD
Email
celine.chauleur@chu-st-etienne.fr
First Name & Middle Initial & Last Name & Degree
Céline CHAULEUR, MD
Facility Name
CHU de Toulouse - Paule de Viguier
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hélène POL, MD
Email
helene.pol@chu-toulouse.fr
First Name & Middle Initial & Last Name & Degree
Fabien VIDAL, MD
First Name & Middle Initial & Last Name & Degree
Yann TANGUY LE GAC, MD
First Name & Middle Initial & Last Name & Degree
Géraldine CARTRON, MD
First Name & Middle Initial & Last Name & Degree
Martin BAUJAT, MD
Facility Name
CHU de Toulouse - Rangueil
City
Toulouse
ZIP/Postal Code
31400
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elodie CHANTALAT, MD
Email
chantalat.e@chu-toulouse.fr
First Name & Middle Initial & Last Name & Degree
Elodie CHANTALAT, MD
First Name & Middle Initial & Last Name & Degree
Jacques RIMAILHO, MD
First Name & Middle Initial & Last Name & Degree
Stéphanie MOTTON, MD
First Name & Middle Initial & Last Name & Degree
Marc SOULE-THOLY, MD
Facility Name
CH de Tulle
City
Tulle
ZIP/Postal Code
19000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
François SIEGERTH, MD
Email
FSIEGERTH@ch-tulle.fr

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32641096
Citation
Lacorre A, Vidal F, Campagne-Loiseau S, Marin B, Aubard Y, Siegerth F, Mesnard C, Chantalat E, Hocke C, Gauthier T. Protocol for a randomized controlled trial to assess two procedures of vaginal native tissue repair for pelvic organ prolapse at the time of the questioning on vaginal prosthesis: the TAPP trial. Trials. 2020 Jul 8;21(1):624. doi: 10.1186/s13063-020-04512-x.
Results Reference
derived

Learn more about this trial

Vaginal Native Tissues Repair for Pelvic Organ Prolapse

We'll reach out to this number within 24 hrs